Therapy News and Research

RSS

Study: Combination treatment more than halves mortality rates for prostate cancer

Combination treatment more than halves mortality rates for prostate cancer, reports Norwegian health journal Dagens Medisin.

30 Jan 2014

EBRT provides higher breast preservation rate in women with invasive breast cancer

Standard external beam radiation therapy (EBRT) provided a higher breast preservation rate than brachytherapy in women age 66 and older with invasive breast cancer, according to a study published in the February 1, 2014 print edition of the International Journal of Radiation Oncology ● Biology ● Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).

30 Jan 2014

Altheus Therapeutics receives patent for oral combination therapy for treating inflammatory bowel disease

Altheus Therapeutics, Inc. announced the USPTO has allowed patent 8,629,127 B2 covering the oral pharmaceutical composition 5-ASA (5-aminosalicylic acid) and NAC (N-acetylcysteine).

30 Jan 2014

Study reveals alarming increase in oropharyngeal cancers among young adults

A new study reveals an alarming increase in oropharyngeal cancers among young adults. While the exact cause for this phenomenon is unknown, the human papillomavirus (HPV) may be to blame.

30 Jan 2014

Researchers discover potential treatment for viral infection that causes illnesses in children

Researchers have discovered a potential treatment for a viral infection that causes potentially fatal brain swelling and paralysis in children. The findings also point to possible treatments for related viruses including those that cause "common cold" symptoms.

29 Jan 2014

Myriad Genetics' Prolaris opens door to a new era of personalized treatment for prostate cancer

Myriad Genetics, Inc. today announced results from PROCEDE 500, a clinical utility study with its Prolaris test, at the 2014 ASCO Genitourinary Cancers Symposium in San Francisco, Calif. The study demonstrated the significant clinical value of Prolaris to physicians who are treating men with prostate cancer. Prolaris is a prognostic test that accurately predicts prostate cancer-specific death and metastases and has been validated in 11 clinical studies with more than 5,000 patients.

29 Jan 2014

Researchers identify new subgroup of patients suffering from schizophrenia with motor disorders

Researchers led by Marta Barrachina, Institute of Neuropathology of the Bellvitge Biomedical Research Institute (IDIBELL) have identified a new subgroup of patients suffering from schizophrenia characterized by motor disorders.

29 Jan 2014

Impaired cognitive insight linked to delusions in psychosis risk

High levels of self-certainty, one aspect of cognitive insight, are associated with the presence of delusional symptoms in people with at-risk mental states, a study shows.

29 Jan 2014

Omeros announces positive results from Phase 2a trial of OMS824 in patients with schizophrenia

Omeros Corporation today announced positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor, in which the drug was well tolerated and demonstrated comparable systemic pharmacokinetics when administered alone and concomitantly with approved antipsychotic agents in patients with schizophrenia. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including schizophrenia and Huntington's disease.

29 Jan 2014

FARA funds gene therapy-based research project to tackle Friedreich's ataxia

The gene therapy-based research project to tackle Friedreich's ataxia launched in November in labs at the Institute for Research in Biomedicine, in Barcelona, and the "Centro de Biolog-a Molecular Severo Ochoa", in Madrid, has received 100,000 US$ per year for two years from the Friedreich's Ataxia Research Alliance.

29 Jan 2014

Aspirin prescribed more often for stroke prevention in AF despite of dangerous side effects

Aspirin is still overprescribed for stroke prevention in atrial fibrillation (AF) despite the potential for dangerous side effects, according to research published today.

29 Jan 2014

Study at Autism Speaks shows improvement towards universal early screening

A new study from researchers at Autism Speaks, the world's leading autism science and advocacy organization, shows improvement towards universal early screening for autism.

29 Jan 2014

Study shows aortic valve replacement have improved with availability of TAVR technology

The introduction of minimally invasive transcatheter aortic valve replacement (TAVR) for treatment of aortic stenos not only has increased the number of patients eligible for aortic valve replacement (AVR), but also has led to a decrease in patient mortality, according to a study released today at the 50th Annual Meeting of The Society of Thoracic Surgeons.

29 Jan 2014

Study shows melatonin hormone may inhibit tumor growth and cell production

An early stage study shows melatonin - a hormone that regulates the body's sleep and awake cycles - may have the potential to help slow the growth of certain breast cancer tumors, according to researchers from Henry Ford Hospital in Detroit and Foundation for Research Support of the State of S-o Paulo.

28 Jan 2014

Everolimus fails to boost advanced NSCLC response

Phase II trial findings have ruled out a combination of erlotinib and everolimus for advanced non-small-cell lung cancer patients with progression after chemotherapy.

28 Jan 2014

Anxiety, depression and meditation: an interview with Dr Madhav Goyal, Johns Hopkins University School of Medicine

We wanted to be broadly inclusive of any kind of meditation program, so we defined a meditation program to be any kind of structured meditation program that involved at a minimum 4 hours of training, with instructions to practice outside the classroom.

28 Jan 2014

Curie-Cancer, Servier renew partnership to identify new therapeutic targets for triple negative breast cancer

Curie-Cancer, the body which leads the Institut Curie's industry partner research activity, and Servier, today announce that they have renewed their partnership with the aim of identifying therapeutic targets for treating ‘triple negative’ breast cancers. The partnership will continue for a further three years.

28 Jan 2014

Medac Pharma announces FDA acceptance of New Drug Application for MPI-2505

Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced the FDA acceptance of its New Drug Application (NDA) for its lead product candidate, MPI-2505, a subcutaneous injectable methotrexate (MTX) in a ready-to-use injection device, for which the proposed indications are rheumatoid arthritis (RA), poly-articular-course juvenile RA and psoriasis.

28 Jan 2014

Cell Therapeutics completes patient enrollment in Phase 3 clinical trial of Opaxio in ovarian cancer

Cell Therapeutics, Inc.today announced that the Gynecologic Oncology Group informed CTI that it has completed patient enrollment in the GOG-0212 Phase 3 clinical trial of investigational agent paclitaxel poliglumex as maintenance therapy in ovarian cancer.

28 Jan 2014

Response of brain tumors from SRS can indicate necessity of follow-up treatments

The response of a patient with metastatic brain tumors to treatment with stereotactic radiosurgery in the first six-to-twelve weeks can indicate whether follow-up treatments and monitoring are necessary, according to research conducted at the University of North Carolina.

28 Jan 2014

Therapy News and Research

Study: Combination treatment more than halves mortality rates for prostate cancer

EBRT provides higher breast preservation rate in women with invasive breast cancer

Altheus Therapeutics receives patent for oral combination therapy for treating inflammatory bowel disease

Study reveals alarming increase in oropharyngeal cancers among young adults

Researchers discover potential treatment for viral infection that causes illnesses in children

Myriad Genetics' Prolaris opens door to a new era of personalized treatment for prostate cancer

Researchers identify new subgroup of patients suffering from schizophrenia with motor disorders

Impaired cognitive insight linked to delusions in psychosis risk

Omeros announces positive results from Phase 2a trial of OMS824 in patients with schizophrenia

FARA funds gene therapy-based research project to tackle Friedreich's ataxia

Aspirin prescribed more often for stroke prevention in AF despite of dangerous side effects

Study at Autism Speaks shows improvement towards universal early screening

Study shows aortic valve replacement have improved with availability of TAVR technology

Study shows melatonin hormone may inhibit tumor growth and cell production

Everolimus fails to boost advanced NSCLC response

Anxiety, depression and meditation: an interview with Dr Madhav Goyal, Johns Hopkins University School of Medicine

Curie-Cancer, Servier renew partnership to identify new therapeutic targets for triple negative breast cancer

Medac Pharma announces FDA acceptance of New Drug Application for MPI-2505

Cell Therapeutics completes patient enrollment in Phase 3 clinical trial of Opaxio in ovarian cancer

Response of brain tumors from SRS can indicate necessity of follow-up treatments

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News